LivaNova (LIVN) to Release Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is scheduled to be announcing its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.47 per share for the quarter. LivaNova has set its FY 2024 guidance at 2.950-3.050 EPS and its FY24 guidance at $2.95-3.05 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to the consensus estimate of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same period last year, the firm posted $0.81 earnings per share. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LivaNova Stock Performance

LivaNova stock opened at $55.02 on Wednesday. The firm’s 50 day simple moving average is $53.77 and its 200-day simple moving average is $50.55. The company has a market cap of $2.97 billion, a P/E ratio of 171.94 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $59.86.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LIVN. Barclays boosted their price objective on shares of LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a research report on Monday, February 26th. StockNews.com downgraded shares of LivaNova from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Mizuho reaffirmed a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Wednesday, March 27th. Robert W. Baird boosted their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a research report on Thursday, February 22nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of LivaNova in a research report on Wednesday, March 20th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, LivaNova presently has an average rating of “Hold” and an average target price of $64.40.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.